BeOne Medicines AG (49BA) Harga & Berita Saham

(USD)	Sep 2025	Perubahan Y/Y
Pendapatan	1,41 M	41,00%
Biaya operasional	1,05 M	10,64%
Penghasilan bersih	124,84 jt	202,88%
Margin laba bersih	8,84	172,94%
Penghasilan per saham	1,09	267,89%
EBITDA	198,86 jt	496,46%
Tarif pajak efektif	15,17%	—

Neraca

Total aset

Total liabilitas

(USD)	Sep 2025	Perubahan Y/Y
Investasi tunai jangka pdk	4,04 M	48,74%
Total aset	7,63 M	31,04%
Total liabilitas	3,50 M	47,29%
Total ekuitas	4,13 M	—
Saham yang beredar	110,66 jt	—
Harga terhadap nilai buku	8,09	—
Tingkat pengembalian aset	5,85%	—
Tingkat pengembalian modal	8,20%	—

Arus Kas

Perubahan kas bersih

(USD)	Sep 2025	Perubahan Y/Y
Penghasilan bersih	124,84 jt	202,88%
Kas dari operasi	402,55 jt	113,70%
Kas dari investasi	-49,27 jt	63,20%
Kas dari pembiayaan	961,27 jt	7.491,79%
Perubahan kas bersih	1,32 M	1.286,91%
Arus kas bebas	306,27 jt	120,68%

Tentang

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia

CEO

Didirikan

28 Okt 2010

Situs

beonemedicines.com

Karyawan

11.000